HEALTHJul 23 · 16:23 UTCSTAT NEWSIsabella Cueto

STAT+: Popular insulin product enters shortage as other pens leave market

Sanofi's Lantus Solostar insulin pen is experiencing supply issues due to increased demand, causing patients to struggle to find medication. The FDA does not classify the situation as a shortage, but Sanofi is accelerating production to address the problem.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

SanofiorganizationLantus SolostarproductFood and Drug Administrationorganizationinsulin glarginetopicdiabetestopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJul 17 · 13:02 UTC
STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
HEALTHMay 7 · 13:47 UTC
STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
HEALTHJun 9 · 20:46 UTC
STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
HEALTHJun 11 · 13:21 UTC
STAT+: Pharmalittle: We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
BUSINESSMay 30 · 19:33 UTC
Off-the-charts demand for a natural healthy sweetener is driving nationwide shortages… and producers are dying off